Market Overview

A Peek Into The Market Before The Trading Starts

Share:
A Peek Into The Market Before The Trading Starts
Related AMAT
Applied Materials Technicals May Be Set For A Slip
Fast Money Halftime Report Final Trade From February 20
Notable tech decliners: AMAT, SONS, SFUN, YGE, DQ, CCIH (Seeking Alpha)
Related BMY
Bristol-Myers Squibb Canada Announces Hepatitis C Cure Rate of 97% in Study of Patients Co-infected with HIV Given 12-week Combination Treatment of Daclatasvir and Sofosbuvir in ALLY-2 Trial
UPDATE: USDA Approves Supplimental Biologics License
Bristol-Myers Backs Bavarian Nordic Cancer Vaccine (Investor's Business Daily)

Pre-open movers US stock futures are higher this morning. Futures for the Dow Jones Industrial Average surged 80 points to 15,218.00 and S&P 500 index futures rose 9.60 points to 1,636.70. Nasdaq 100 futures gained 14 points to 2,977.50.

A Peek Into Global Markets European markets were higher today. The STOXX Europe 600 Index gained 0.55%, London's FTSE 100 index gained 0.21%, French CAC 40 Index rose 0.43% and German DAX 30 index rose 0.08%.

Asian markets ended lower, with Japan's Nikkei Stock Average falling 0.21% and Australia's ASX/S&P500 dropping 0.69%. India's Sensex tumbled 0.53%.

Broker Recommendation Analysts at Citigroup upgraded Applied Materials (NASDAQ: AMAT) from “neutral” to “buy.” The target price for Applied Materials has been raised from $14 to $20.

Applied Materials shares closed at $15.19 yesterday.

Breaking news

  • Bristol-Myers Squibb Company (NYSE: BMY) today announced the results of year two data from AMPLE (Abatacept Versus Adalimumab Comparison in Biologic-Naïve rheumatoid arthritis (RA) Subjects With Background Methotrexate), a first-of-its-kind trial of 646 patients comparing the subcutaneous (SC) formulation of ORENCIA® (abatacept) vs. Humira® (adalimumab), each on a background of MTX, in biologic naïve patients with moderate to severe RA. To read the full news, click here.
  • Gigamon (NYSE: GIMO) announced today the pricing of its initial public offering of 6,750,000 shares of its common stock at a price to the public of $19.00 per share. To read the full news, click here.
  • Portland General Electric Company (NYSE: POR) announced today the pricing of a public offering of 11.1 million shares of its common stock at $29.50 per share. To read the full news, click here.
  • Cyber-security expert Avira Technologies (NYSE: AVG) announced today that Travis Witteveen has been promoted to CEO of the company, effective July 1, 2013. To read the full news, click here.

Posted-In: Citigroup US Stock FuturesNews Futures Global Pre-Market Outlook Markets

 

Related Articles (AMAT + AVG)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Benzinga PRO content